PUBLIC COMPANY
saveGan & Lee Pharmaceuticals Co Ltd
updated 5mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology2 co-mentions · 1 sources
- tagType 2 Diabetes2 co-mentions · 1 sources
- druginsulin aspart2 co-mentions · 1 sources
- drugFiasp2 co-mentions · 1 sources
- druginsulin2 co-mentions · 1 sources
- tagPulmonology1 co-mentions · 1 sources
- tagEndocrinology & Metabolism1 co-mentions · 1 sources
- tagProstate Cancer1 co-mentions · 1 sources
pipeline
6
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Preclinical1Phase 23pre_registration1Unknown
Phase 2
bofanglutide
Obesity
PreclinicalGLR-2007
Malignant Glioma
drugGLR-2037
pre_registrationinsulin aspart
Type 1 Diabetes (Juvenile Diabetes)
Insulin receptor
pre_registrationinsulin glargine LA
Type 1 Diabetes (Juvenile Diabetes)
Insulin receptor
pre_registrationinsulin lispro
Type 1 Diabetes (Juvenile Diabetes)
Insulin receptor
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
- phase1Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
- phase1Bioequivalence Study of GZR18 Injection Before and After CMC Change
- phase1A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
- phase1Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
- phase1A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
- phase2Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
- phase3Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that